Background: Successful treatment of vascular anomalies represents a challenging problem despite using various treatments. Intralesional injection of bleomycin has been successfully used in treatment of macrocystic lymphatic malformations and hemangiomas, based specifically on a high sclerosing effect on vascular endothelium. Methods: In a prospective study of 75 patients, there were 47 women and 28 men. Their ages ranged from 3 to 35 years with a mean age of 14 years. The effectiveness of intralesional bleomycin injection in hemangiomas and vascular malformations was evaluated.
V ascular anomalies are among the most common forms of congenital and neonatal dysmorphogenesis, which represent a wide spectrum of pathological conditions with different clinical characteristics, natural evolution, and therapeutic approaches. They can occur in various areas throughout the body with 60% being located in the head and neck. These pathological conditions were commonly merged under the term hemangioma in the past. A clear classification separating vascular tumors (with hemangiomas being the most common) from congenital vascular malformations was developed by Mulliken and Glowacki 1 in 1982 based on clinical behavior, histology, and histochemistry. This classification was accepted by the International Society for the Study of Vascular Anomalies at the June 1996 workshop in Rome. 2 The subsequent modified classification by Waner and Suen 3 is more distinct and practical. Vascular malformations are subdivided into slow flow (capillary, lymphatic, and venous) and fast flow (arterial, arteriovenous fistulae, and arteriovenous malformation). Lymphatic can be described as microcystic, macrocystic, or combined (micro-macrocystic). There are many treatment options for vascular anomalies documented in the literatures, including laser therapy, sclerotherapy, embolization, electrochemical therapy, copper needle treatment, surgical resection, and a combination of these. The selection of the treatment modalities depends on the type, location, and size of the lesions, the patients' status, and techniques available. Surgical excision has been the favored treatment modality for vascular malformations in the head and neck area. However, some lesions may be difficult to remove when they permeate and envelop vital structures such as facial nerve, so a less-invasive mode of therapy may prevent damage to these vital structures. 4 Percutaneous sclerotherapy was developed as a minimally invasive treatment modality for these lesions. It is usually safe and effective for small-and medium-sized malformations, and it has also proved helpful as a preoperative adjunctive treatment of large lesions to reduce surgical blood loss and to delineate the surgical extent of resection. 5 Agents like bleomycin, 6 Ethibloc, 7 and OK-432 8 have now been used for percutaneous sclerotherapy.
PATIENTS AND METHODS
A prospective study between January 2009 and June 2011 was performed on a total of 75 patients who presented with vascular anomalies, either hemangioma or vascular malformation. They were admitted in both the Plastic Surgery Department and Pediatric Surgery Unit in Assiut University Hospital. There were 47 women and 28 men. Their ages ranged from 3 to 35 years with a mean age of 14 years. All patients presented with a sizable lesion (Figs. 1Y5).
Informed consent was given for the use of bleomycin as injection therapy. A standardized sheet recording patients' details included age, sex, weight, location of lesion, size, clinical history, special investigations, bleomycin dose, clinical response, adverse effects, and follow-up. The response was recorded by serial photography and measurement before, during, and after completion of the treatment. Of the 75 patients included, 33 (44%) patients have hemangiomas and 42 (56%) patients have vascular malformations.
Bleomycin powder (15 mg) was reconstituted with 15 mL of normal saline (dilution 1 mg/mL).
Dosage regimens used were as follows: Y In children younger than 1 year, the maximum dose per injection was limited to 0.5 to 1 mg/kg and varied according to the size of the lesion. Y In children older than 1 year and adults, a dose of 1 to 15 mg was injected intralesionally per session.
A single dose of 15 mg per session was never exceeded. The needle was introduced through normal skin, if possible, and advanced into the hemangioma or vascular malformation in the subcutaneous and deep tissue planes. Subdermal injection was administered to superficial lesions with caution to use small volumes to prevent ulceration. Injection was followed by local pressure application for a period of 5 to 10 minutes, after which a pressure dressing was applied. In cases of superficial lesions of the face, neck, and genitalia with risk of ulceration and subsequent poor cosmetic result, a dilution of 0.6 mg/mL was used. The volume injected was matched to the lesion size based on a trial and error basis initially and later standardized to a degree. Exact protocols are difficult to determine because of the heterogeneity of the lesions and multilevel involvement of the tissue. Duration of 3 to 4 weeks was found to be consistent with the expected changes in hemangioma and vascular malformations. A change in lesion size and appearance is often not detectable until the third injection has been completed. The average course for injection varied from 3 to 4 sessions with maximum 6 sessions. Most of our patients (69) were done in outpatient clinic without need for any type of anesthesia; topical anesthetic cream was applied 15 minutes before injection. Only 6 children younger than 4 years needed general anesthesia in the operation room. The course after intralesional bleomycin injection treatment was uneventful in most patients, who were discharged 1 to 3 hours postinjection with mild analgesia. Mild swelling and pain disappeared from 24 to 48 hours after the treatment.
The follow-up of these patients were done in an outpatient clinic, focusing on certain parameters, namely size, color, and texture of the lesion after treatment. Aesthetic appearance was documented by preinjection and postinjection photography using a digital camera. The period of follow-up varied from 4 to 30 months.
RESULTS
The results were scored according to a 4-point scale modified after Achauer et al 9 based on improvement in volume, color, and texture after treatment. 1VNo response, that is, no change in the size or continued to enlarge. 2VMild improvement, that is, the lesions decreased in size, but less than 50% with improvement in appearance. 3VMarked improvement, that is, the lesions decreased in size more than 51%, but less than 100% with remarkable improvement in appearance. 4VCured, that is, the lesions disappeared completely without recurrence at least 6 months after treatment. Local complications encountered were superficial ulceration occurring in 5 patients that required surgical intervention by direct closure and acceptable aesthetic appearance caused by marked reduction of the size secondary to injection. Although nausea and vomiting was not a common feature, 1 patient developed vomiting twice after injection and responded well to an antiemetic.
Systemic complications were flu-like symptoms in 3 patients. None of the patients presented with hematological toxic effects or signs of pulmonary fibrosis, and/or hypertension. The presence of pulmonary complication was excluded by preinjection and postinjection clinical and radiological evaluation and then spirometry (D 97723; Zan 300, Oberthulba, Germany) for patients older than 12 years.
DISCUSSION
Sclerotherapy is an injection of a sclerosing substance directly through the skin into a lesion and is used for vascular anomalies, particularly for venous and lymphatic malformations. Various sclerotherapy agents were used for venous malformation in the past. Ethanol is a very potent sclerosant and has the risk of nerve injury and skin necrosis. When ethanol directly enters the systemic veins, the patient can develop cardiovascular collapse.
Ethibloc is another agent, and this was licensed in West Germany in 1979. It was used in the treatment of a venous malformation. Ethibloc has adverse effects including pain, swelling, and ecchymosis. It caused fistulization to the skin from the venous malformation, leading to leakage of the Ethibloc from the wound. It also caused phlebitis.
OK-432 was classified as a potent biological response modifier. It was used for lymphatic malformation and the adverse effects were fever and swelling. Ethibloc and OK-432 are not approved for use in the United States. 10 The embolization technique has been used on capillary-venous malformation, and there were following limitations, the devascularization is rarely complete as it is not possible to embolize every feeding vessel. An expert interventional radiologist team is required to carry out embolization, also it was expensive and an invasive tool.
Bleomycin was developed as an antitumor agent by Umezawa 11 in 1966. Mechanistically, it acts through inhibition of DNA synthesis. 11 Yura et al 12 first used bleomycin as a sclerosing agent in lymphangiomas. Tanigawa et al 13 in 1987 injected bleomycin into aspirated cyst cavities in macrocystic lymphatic malformation. The most serious complication of the use of bleomycin is pulmonary fibrosis when it is administered during cancer therapy. The risk of this toxicity is felt to be minimal when the dose per treatment is kept under 1 mg/kg per session and used no more frequently than an interval of 3 weeks, with the total dose limited to 5 mg/kg. The doses were always far below those used for antineoplastic indications. 14 In our study, the dose did not exceed this standard dose; also we keep an interval of 3 to 4 weeks between injections. This study recorded cure rate and marked improvement in 71% of cases, which required no surgery, with accepted aesthetic appearance. This shows that this simple noninvasive technique is quite an effective tool in the management of hemangioma and vascular malformation. Also in this study, there was mild improvement in 14 (18.5%) cases, which reduced the size and vascularity of the lesions and facilitated later aesthetic surgical closure with minimal adverse effects. Most of our patients (69 patients) were done in the outpatient clinic requiring only topical anesthetic cream, precluding the risk of anesthesia and also saving the cost of a long hospital staying. 
